
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$25.35
−US$0.19 · -0.74%
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
常规交易时段
US$25.35
−US$0.19 · -0.74%
盘中时间采用ET。市场数据可能有所延迟。
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
日内区间
当前US$25.35
52周区间
当前US$25.35
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
83
深度低估
情绪
64
看涨
风险
57
风险偏高
动量
26
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
日内区间
当前US$25.35
52周区间
当前US$25.35
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.2亿 USD | 7.32亿 USD | 6.44亿 USD | 4.99亿 USD | 4.38亿 USD |
| 销货成本 | 3.64亿 USD | 3.58亿 USD | 2.93亿 USD | 2.5亿 USD | 2.38亿 USD |
| 毛利 | 3.56亿 USD | 3.74亿 USD | 3.51亿 USD | 2.49亿 USD | 2亿 USD |
| 研究与开发 | 8584.4万 USD | 7391.4万 USD | 7374.1万 USD | 7477.1万 USD | 6093.2万 USD |
| 销售、一般及管理费用 | 1.3亿 USD | 9452.2万 USD | 8039.3万 USD | 6659.2万 USD | 6892万 USD |
| 营业费用 | 2.16亿 USD | 1.68亿 USD | 1.54亿 USD | 1.41亿 USD | 1.3亿 USD |
| 利息收入 | 867.9万 USD | 1061.2万 USD | 545.9万 USD | 132.1万 USD | 60.1万 USD |
| 利息支出 | 2548.1万 USD | 3034.3万 USD | 2715.8万 USD | 184.6万 USD | 88.5万 USD |
| 折旧和摊销 | 6320.1万 USD | 5720.5万 USD | 4177.7万 USD | 2827.5万 USD | 2546.2万 USD |
| 营业利润 | 1.4亿 USD | 2.05亿 USD | 1.97亿 USD | 1.07亿 USD | 6988.7万 USD |
| 净利润 | 9809.4万 USD | 1.6亿 USD | 1.38亿 USD | 9138.6万 USD | 6211.6万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$21.25
下跌空间 16.17%年度分割调整后的每股现金分配。
US$0.30
2010年(完整年度)0.0% 自从 2009
US$0.30
2,009
US$0.30
2,010
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2010年6月11日 | US$0.30Annual | — | 2010年6月30日 |
股息 | 2009年6月11日 | US$0.30Annual | — | 2009年6月30日 |
除息 2010年6月11日
US$0.30
Annual
支付日 2010年6月30日
除息 2009年6月11日
US$0.30
Annual
支付日 2009年6月30日
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR4805.62万0.05%1042.94亿 USD0.06%US$136.73-0.26%
Avantis U.S. Small Cap Value ETFAVUV3429.49万0.11%305.4亿 USD0.25%US$119.44+0.26%
Vanguard Morningstar Total Stock Market ETFVTI2378.44万0.00%2.3万亿 USD0.03%US$380.24-0.21%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2230.91万0.08%266.88亿 USD0.33%US$37.845+0.13%
iShares Russell 2000 ETFIWM2192.79万0.03%785.63亿 USD0.19%US$276.8-0.32%
Dimensional - US Targeted Value ETFDFAT1375.62万0.05%300.02亿 USD0.33%US$67.07-0.01%
Vanguard Extended Market ETFVXF891.53万0.01%954亿 USD0.05%US$232.73-0.33%
Dimensional - US Small Cap ETFDFAS866.18万0.03%336.6亿 USD0.31%US$77.735-0.24%
iShares Core S&P Small-Cap ETFIJR
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
iShares Russell 2000 ETFIWM
Dimensional - US Targeted Value ETFDFAT
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。